Longevity & AgingCagriSema Combo Slashes Blood Sugar and Weight Across Type 2 Diabetes Stages
A new injectable combination drug called CagriSema — pairing the GLP-1 drug semaglutide with a novel amylin analog called cagrilintide — significantly reduced blood sugar and body weight in three large phase III trials involving people with type 2 diabetes. Presented at the American Diabetes Association annual meeting and published simultaneously in The Lancet journals, the REIMAGINE trials tested CagriSema across early-stage, intermediate, and advanced type 2 diabetes. In early-stage patients, the higher dose cut HbA1c by 1.8 percentage points and drove roughly 12% greater weight loss versus placebo. Benefits extended to patients on standard medications and those using basal insulin. Side effects were mostly mild gastrointestinal issues, consistent with the GLP-1 drug class. Experts note a head-to-head comparison with tirzepatide would help define CagriSema's place in treatment.
